Replies to post #273 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Aren't [Merrimack] a bit behind the original guidance on that?<

Only slightly. Merrimack’s guidance for the phase-2b RA results has been “midyear.”

>I am also surprised that a hostile takeover attempt has not happened at these oversold prices.<

A hostile takeover is one thing you do not need to worry about, IMO. When was the last time a hostile takeover occurred in biotech?